FDA Approves Durvalumab for Muscle Invasive Bladder Cancer By Ogkologos - May 2, 2025 574 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the NIAGARA study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide on Cancer Pain Management Now Available Also in French FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment MOST POPULAR October is National Dental Hygiene Month October 1, 2020 Why haven’t we cured cancer? June 20, 2022 FDA Approves Nivolumab in Combination with Cisplatin and Gemcitabine for Unresectable... March 15, 2024 Prospective Evaluation of Benefit in Patients with Advanced Cancer Treated with... February 8, 2023 Load more HOT NEWS FDA Grants Regular Approval to Sacituzumab Govitecan for Advanced Triple-Negative Breast... FDA Grants Accelerated Approval to Tafasitamab-cxix for DLBCL EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin and Pembrolizumab Doing More—Together—to End Cancer as We Know It
